Challenges in Managing Biochemical Recurrence after Prostate Cancer Surgery

A new study on personalized medicine has shed light on the challenges in managing biochemical recurrence (BCR) after radical prostatectomy and postoperative radiotherapy for prostate cancer (PCa). The research highlights the gaps in risk stratification, imaging, and emerging therapies, as well as advances in molecular imaging and personalized treatment. Approximately half of PCa patients experience a second BCR after postoperative radiotherapy.

Key Takeaways:

• Biochemical recurrence after radical prostatectomy and postoperative radiotherapy is a significant challenge in PCa management, with approximately half of patients experiencing a second BCR.
• Risk stratification is key for guiding the addition of androgen deprivation therapy (ADT) and novel androgen receptor pathway inhibitors (ARPIs) to standard treatment.
• Prostate-specific membrane antigen (PSMA) PET has emerged as a promising tool for detecting recurrent disease and guiding tailored strategies such as metastasis-directed therapy (MDT).
• MDT has demonstrated promising efficacy in oligorecurrent PCa, although further validation is warranted.
• Ongoing trials will clarify treatment sequencing and patient selection in the evolving paradigm of BCR management.
• Key factors for risk stratification include time to recurrence, PSA kinetics, adverse pathological features, and genetic profile.
• Combination of ADT and ARPIs is an established treatment choice, but recent findings emphasize the growing role of PSMA PET in detecting recurrent disease.

Statistics:

• Approximately half of PCa patients experience a second BCR after postoperative radiotherapy.
• 50% of patients experience BCR after radical prostatectomy and postoperative radiotherapy.
• Current evidence suggests that PSMA PET may refine tailored strategies such as MDT, whose promising efficacy needs further exploration.
• Early phase II trials and retrospective studies have demonstrated promising efficacy of MDT in oligorecurrent PCa.

Sources:

• Biochemical recurrence after radical prostatectomy and postoperative radiotherapy: current evidence and controversial issues. Current Opinion in Urology, 2025.
• University of Montreal Health Center Reports Findings in Personalized Medicine (Biochemical recurrence after radical prostatectomy and postoperative radiotherapy: current evidence and controversial issues). Chemicals & Chemistry. May 23, 2025; p 4540.